Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a cardioprotective agent presented as an oral tablet. It is used to improve myocardial energy metabolism in patients with ischemic heart disease, angina pectoris, heart failure and cerebral ischemia, helping to increase tolerance to reduced oxygen supply.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing consistent quality and regulatory compliance for global healthcare providers, including both public and private sector institutions, with established logistics for timely delivery.

Mildronate (meldonium) is employed in the management of cardiovascular and cerebrovascular conditions characterized by reduced oxygen supply.

Ischemic heart disease: improves myocardial tolerance to ischemia and reduces anginal episodes. Angina pectoris: decreases frequency and severity of chest pain during exertion. Heart failure: supports cardiac output by optimizing myocardial energy use. Cerebral ischemia: may enhance neuronal resistance to hypoxic injury.

Mildronate is generally well tolerated, but adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nausea: occasional gastrointestinal discomfort. - Dizziness: sensation of light‑headedness, especially on standing. - Insomnia: difficulty initiating or maintaining sleep. - Fatigue: feeling of reduced energy. - Gastrointestinal upset: mild abdominal discomfort.

Serious or Rare Side Effects: - Hypotension: marked drop in blood pressure requiring monitoring. - Cardiac arrhythmia: irregular heart rhythm, potentially symptomatic. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Elevated liver enzymes: indication of hepatic stress. - Skin rash: extensive or blistering eruptions. - Myocardial injury: rare cases of worsening cardiac function.

Before initiating Mildronate, clinicians should consider several safety measures.

Assess cardiac function: perform baseline evaluation of heart status. Monitor blood pressure: check regularly for hypotensive episodes. Renal impairment: adjust use in patients with reduced kidney function. Hypersensitivity: avoid in individuals with known allergy to meldonium. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at ambient temperature (below 25 °C): keep in the original pack, protect from moisture.

Mildronate may interact with other cardiovascular and metabolic agents.

Major Interactions (Avoid): - Concomitant use with other metabolic modulators (e.g., trimetazidine) may increase risk of hypotension. - Strong CYP450 inhibitors: although meldonium is not a major CYP substrate, co‑administration could alter drug levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and blood pressure. - Antihypertensives: watch for additive blood‑pressure‑lowering effects. - Diuretics: observe electrolyte balance and renal function.